Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2

被引：520

作者：

Collier, Dami A. ^{[1
,2
,3
]}

Ferreira, Isabella A. T. M. ^{[1
,2
]}

Kotagiri, Prasanti ^{[1
,2
]}

Datir, Rawlings P. ^{[1
,2
,3
]}

Lim, Eleanor Y. ^{[2
]}

Touizer, Emma ^{[3
]}

Meng, Bo ^{[1
,2
]}

Abdullahi, Adam ^{[1
]}

Elmer, Anne ^{[4
,5
]}

Kingston, Nathalie ^{[4
,5
]}

Graves, Barbara ^{[4
]}

Le Gresley, Emma ^{[4
,5
]}

Caputo, Daniela ^{[4
,5
]}

Bergamaschi, Laura ^{[1
]}

Smith, Kenneth G. C. ^{[1
,2
]}

Bradley, John R. ^{[2
,4
]}

Ceron-Gutierrez, Lourdes ^{[6
]}

Cortes-Acevedo, Paulina ^{[7
]}

Barcenas-Morales, Gabriela ^{[7
]}

Linterman, Michelle A. ^{[8
]}

McCoy, Laura E. ^{[3
]}

Davis, Chris ^{[9
]}

Thomson, Emma ^{[9
]}

Lyons, Paul A. ^{[1
,2
]}

McKinney, Eoin ^{[1
,2
]}

Doffinger, Rainer ^{[5
]}

Wills, Mark ^{[1
,2
]}

Gupta, Ravindra K. ^{[1
,2
]}

机构：

[1] Cambridge Inst Therapeut Immunol & Infect Dis CIT, Cambridge, England

[2] Univ Cambridge, Dept Med, Cambridge, England

[3] UCL, Div Infect & Immun, London, England

[4] NIHR Bioresource, Cambridge, England

[5] Univ Cambridge, Sch Clin Med, Dept Publ Hlth & Primary Care, Cambridge Biomed Campus, Cambridge, England

[6] Addenbrookes Hosp, Dept Clin Biochem & Immunol, Cambridge, England

[7] Univ Nacl Autonoma Mexico, Lab Inmunol, FES Cuautitlan, Mexico City, DF, Mexico

[8] Babraham Inst, Immunol Programme, Cambridge, England

[9] Univ Glasgow, MRC Ctr Virus Res, Glasgow, Lanark, Scotland

来源：

NATURE | 2021年 / 596卷 / 7872期

基金：

英国生物技术与生命科学研究理事会; 英国惠康基金; 英国医学研究理事会;

关键词：

D O I：

10.1038/s41586-021-03739-1

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Although two-dose mRNA vaccination provides excellent protection against SARS-CoV-2, there is little information about vaccine efficacy against variants of concern (VOC) in individuals above eighty years of age(1). Here we analysed immune responses following vaccination with the BNT162b2 mRNA vaccine(2) in elderly participants and younger healthcare workers. Serum neutralization and levels of binding IgG or IgA after the first vaccine dose were lower in older individuals, with a marked drop in participants over eighty years old. Sera from participants above eighty showed lower neutralization potency against the B.1.1.7 (Alpha), B.1.351 (Beta) and P.1. (Gamma) VOC than against the wild-type virus and were more likely to lack any neutralization against VOC following the first dose. However, following the second dose, neutralization against VOC was detectable regardless of age. The frequency of SARS-CoV-2 spike-specific memory B cells was higher in elderly responders (whose serum showed neutralization activity) than in non-responders after the first dose. Elderly participants showed a clear reduction in somatic hypermutation of class-switched cells. The production of interferon-gamma and interleukin-2 by SARS-CoV-2 spike-specific T cells was lower in older participants, and both cytokines were secreted primarily by CD4 T cells. We conclude that the elderly are a high-risk population and that specific measures to boost vaccine responses in this population are warranted, particularly where variants of concern are circulating.

引用

页码：417 / +

页数：23

共 26 条

[1] Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults [J].

Anderson, E. J. ;

Rouphael, N. G. ;

Widge, A. T. ;

Jackson, L. A. ;

Roberts, P. C. ;

Makhene, M. ;

Chappell, J. D. ;

Denison, M. R. ;

Stevens, L. J. ;

Pruijssers, A. J. ;

McDermott, A. B. ;

Flach, B. ;

Lin, B. C. ;

Doria-Rose, N. A. ;

O'Dell, S. ;

Schmidt, S. D. ;

Corbett, K. S. ;

Swanson, P. A., II ;

Padilla, M. ;

Neuzil, K. M. ;

Bennett, H. ;

Leav, B. ;

Makowski, M. ;

Albert, J. ;

Cross, K. ;

Edara, V. V. ;

Floyd, K. ;

Suthar, M. S. ;

Martinez, D. R. ;

Baric, R. ;

Buchanan, W. ;

Luke, C. J. ;

Phadke, V. K. ;

Rostad, C. A. ;

Ledgerwood, J. E. ;

Graham, B. S. ;

Beigel, J. H. .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (25) :2427-2438

[2] Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine [J].

Baden, Lindsey R. ;

El Sahly, Hana M. ;

Essink, Brandon ;

Kotloff, Karen ;

Frey, Sharon ;

Novak, Rick ;

Diemert, David ;

Spector, Stephen A. ;

Rouphael, Nadine ;

Creech, C. Buddy ;

McGettigan, John ;

Khetan, Shishir ;

Segall, Nathan ;

Solis, Joel ;

Brosz, Adam ;

Fierro, Carlos ;

Schwartz, Howard ;

Neuzil, Kathleen ;

Corey, Larry ;

Gilbert, Peter ;

Janes, Holly ;

Follmann, Dean ;

Marovich, Mary ;

Mascola, John ;

Polakowski, Laura ;

Ledgerwood, Julie ;

Graham, Barney S. ;

Bennett, Hamilton ;

Pajon, Rolando ;

Knightly, Conor ;

Leav, Brett ;

Deng, Weiping ;

Zhou, Honghong ;

Han, Shu ;

Ivarsson, Melanie ;

Miller, Jacqueline ;

Zaks, Tal .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (05) :403-416

[3]

Burton OT, 2020, BIORXIV, DOI [10.1101/2020.10.27.357426, DOI 10.1101/2020.10.27.357426]

[4] Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies [J].

Collier, Dami A. ;

De Marco, Anna ;

Ferreira, Isabella A. T. M. ;

Meng, Bo ;

Datir, Rawlings P. ;

Walls, Alexandra C. ;

Kemp, Steven A. ;

Bassi, Jessica ;

Pinto, Dora ;

Silacci-Fregni, Chiara ;

Bianchi, Siro ;

Tortorici, M. Alejandra ;

Bowen, John ;

Culap, Katja ;

Jaconi, Stefano ;

Cameroni, Elisabetta ;

Snell, Gyorgy ;

Pizzuto, Matteo S. ;

Pellanda, Alessandra Franzetti ;

Garzoni, Christian ;

Riva, Agostino ;

Elmer, Anne ;

Kingston, Nathalie ;

Graves, Barbara ;

Mccoy, Laura E. ;

Smith, Kenneth G. C. ;

Bradley, John R. ;

Temperton, Nigel ;

Ceron-Gutierrez, Lourdes ;

Barcenas-Morales, Gabriela ;

Harvey, William ;

Virgin, Herbert W. ;

Lanzavecchia, Antonio ;

Piccoli, Luca ;

Doffinger, Rainer ;

Wills, Mark ;

Veesler, David ;

Corti, Davide ;

Gupta, Ravindra K. .

NATURE, 2021, 593 (7857) :136-+

[5]

Department of Health, 2021, BRIEF RESCH 2 DOS PF

[6] Features of 20133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study [J].

Docherty, Annemarie B. ;

Harrison, Ewen M. ;

Green, Christopher A. ;

Hardwick, Hayley E. ;

Pius, Riinu ;

Norman, Lisa ;

Holden, Karl A. ;

Read, Jonathan M. ;

Dondelinger, Frank ;

Carson, Gail ;

Merson, Laura ;

Lee, James ;

Plotkin, Daniel ;

Sigfrid, Louise ;

Halpin, Sophie ;

Jackson, Clare ;

Gamble, Carrol ;

Horby, Peter W. ;

Nguyen-Van-Tam, Jonathan S. ;

Ho, Antonia ;

Russell, Clark D. ;

Dunning, Jake ;

Openshaw, Peter Jm ;

Baillie, J. Kenneth ;

Semple, Malcolm G. .

BMJ-BRITISH MEDICAL JOURNAL, 2020, 369

[7]

Feng S., CORRELATES PROTECTIO, DOI 10.1101/2021.06.21.21258528(2021

[8] Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant [J].

Graham, Carl ;

Seow, Jeffrey ;

Huettner, Isabella ;

Khan, Hataf ;

Kouphou, Neophytos ;

Acors, Sam ;

Winstone, Helena ;

Pickering, Suzanne ;

Galao, Rui Pedro ;

Dupont, Liane ;

Lista, Maria Jose ;

Jimenez-Guardeno, Jose M. ;

Laing, Adam G. ;

Wu, Yin ;

Joseph, Magdalene ;

Muir, Luke ;

van Gils, Marit J. ;

Ng, Weng M. ;

Duyvesteyn, Helen M. E. ;

Zhao, Yuguang ;

Bowden, Thomas A. ;

Shankar-Hari, Manu ;

Rosa, Annachiara ;

Cherepanov, Peter ;

McCoy, Laura E. ;

Hayday, Adrian C. ;

Neil, Stuart J. D. ;

Malim, Michael H. ;

Doores, Katie J. .

IMMUNITY, 2021, 54 (06) :1276-+

[9]

Israelow B., 2021, ADAPTIVE IMMUNE DETE, DOI 10.1101/2021.05.19.444825(2021

[10] Why the elderly appear to be more severely affected byCOVID-19: The potential role of immunosenescence andCMV [J].

Kadambari, Seilesh ;

Klenerman, Paul ;

Pollard, Andrew J. .

REVIEWS IN MEDICAL VIROLOGY, 2020, 30 (05)

← 1 2 3 →